Literature DB >> 12648303

Hydrolysis of bimatoprost (Lumigan) to its free acid by ocular tissue in vitro.

Sean S Davies1, Won-Kyu Ju, Arthur H Neufeld, Daniel Abran, Sylvain Chemtob, L Jackson Roberts.   

Abstract

We determined whether bimatoprost, which has been reported to act via putative prostamide receptors, could be hydrolyzed to its free acid (17-phenyl-PGF(2 alpha)), a potent FP receptor agonist, by human ocular tissue in vitro. We developed a gas chromatography/mass spectrometric method to measure 17-phenyl-PGF(2 alpha) levels at sub-picomolar levels. We then analyzed the amount of 17-phenyl-PGF(2 alpha) present after incubation of 50 microl Lumigan (0.03% bimatoprost) with eye tissue using this assay. We found that cornea, sclera, iris, and ciliary body, all rapidly hydrolyzed bimatoprost to 17-phenyl-PGF(2 alpha) with linear kinetics at a rate of 6.3, 2.0, 2.8, and 1.5 pmol mg tissue(-1) hr(-1), respectively. For cornea, sclera, and ciliary body, this linear rate of hydrolysis continued over a period of at least three hours, while iris-induced hydrolysis did not continue beyond one hour. Our findings suggest that bimatoprost can act as prodrug for FP receptor activation and questions the concept of a "prostamide receptor" agonist.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12648303     DOI: 10.1089/108076803762718105

Source DB:  PubMed          Journal:  J Ocul Pharmacol Ther        ISSN: 1080-7683            Impact factor:   2.671


  16 in total

1.  Discovery to Launch of Anti-allergy (Emadine; Patanol/Pataday/Pazeo) and Anti-glaucoma (Travatan; Simbrinza) Ocular Drugs, and Generation of Novel Pharmacological Tools Such as AL-8810.

Authors:  Najam A Sharif
Journal:  ACS Pharmacol Transl Sci       Date:  2020-11-05

2.  Comparison of the effects of bimatoprost and timolol on intraocular pressure and pulsatile ocular blood flow in patients with primary open-angle glaucoma: A prospective, open-label, randomized, two-arm, parallel-group study.

Authors:  Michele Vetrugno; Nicola Cardascia; Francesco Cantatore; Carlo Sborgia
Journal:  Curr Ther Res Clin Exp       Date:  2004-11

Review 3.  Prostaglandin FP receptor antagonists: discovery, pharmacological characterization and therapeutic utility.

Authors:  Najam A Sharif; Peter G Klimko
Journal:  Br J Pharmacol       Date:  2018-06-07       Impact factor: 8.739

4.  Studies using isolated uterine and other preparations show bimatoprost and prostanoid FP agonists have different activity profiles.

Authors:  June Chen; Judith Senior; Kay Marshall; Farhat Abbas; Helen Dinh; Tim Dinh; Larry Wheeler; David Woodward
Journal:  Br J Pharmacol       Date:  2005-02       Impact factor: 8.739

5.  First-line treatment for elevated intraocular pressure (IOP) associated with open-angle glaucoma or ocular hypertension: focus on bimatoprost.

Authors:  Simon K Law
Journal:  Clin Ophthalmol       Date:  2007-09

6.  Endogenous Bioactive Lipids and the Regulation of Conventional Outflow Facility.

Authors:  Zhou Wan; David F Woodward; W Daniel Stamer
Journal:  Expert Rev Ophthalmol       Date:  2008

Review 7.  Bimatoprost: a review of its use in open-angle glaucoma and ocular hypertension.

Authors:  Monique P Curran
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

8.  Bimatoprost, prostamide activity, and conventional drainage.

Authors:  Zhou Wan; David F Woodward; Clive L Cornell; Hans G Fliri; José L Martos; Simon N Pettit; Jenny W Wang; Alexander B Kharlamb; Larry A Wheeler; Michael E Garst; Kari J Landsverk; Craig S Struble; W Daniel Stamer
Journal:  Invest Ophthalmol Vis Sci       Date:  2007-09       Impact factor: 4.799

Review 9.  Prostamides (prostaglandin-ethanolamides) and their pharmacology.

Authors:  D F Woodward; Y Liang; A H-P Krauss
Journal:  Br J Pharmacol       Date:  2007-08-27       Impact factor: 8.739

10.  Role of prostaglandins and specific place in therapy of bimatoprost in the treatment of elevated intraocular pressure and ocular hypertension: A closer look at the agonist properties of bimatoprost and the prostamides.

Authors:  Scott D Smid
Journal:  Clin Ophthalmol       Date:  2009-12-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.